Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Purpose: To determine how often loss of ataxia-telangiectasia–mutated (ATM) protein expression occurs in primary pancreatic ductal adenocarcinomas and to determine its prognostic significance. Experimental Design: The expression of ATM and TP53 was determined by immunohistochemistry in 397 surgically resected pancreatic ductal adenocarcinomas (Hopkins; Johns Hopkins Medical Institutions, Baltimore, MD), a second set of 159 cases (Emory; Emory University Hospital, Atlanta, GA), and 21 cancers after neoadjuvant chemoradiotherapy. Expression was correlated with the clinicopathologic parameters, including survival. Results: Tumoral ATM loss was observed in one cancer known to have biallelic inactivation of ATM and 50 of the first 396 (12.8%) cases, significantly more often in patients with a family history of pancreatic cancer (12/49; 24.5%) than in those without (38/347; 11.0%; P = 0.019). In the Hopkins series, ATM loss was associated with a significantly decreased overall survival in patients whose cancers had normal TP53 expression (P = 0.019) and was a significant independent predictor of decreased overall survival (P = 0.014). Seventeen (10.7%) of 159 Emory cases had tumoral ATM loss and tumoral ATM loss/normal TP53 was associated with poorer overall survival (P = 0.1). Multivariate analysis of the combined Hopkins/Emory cases found that tumoral ATM loss/normal TP53 was an independent predictor of decreased overall survival [HR = 2.61; confidence interval (CI), 1.27–5.37; P = 0.009]. Of 21 cancers examined after neoadjuvant chemoradiotherapy, one had tumoral loss of ATM; it had no histologic evidence of tumor response. Conclusions: Tumoral loss of ATM protein was detected more often in patients with a family history of pancreatic cancer than in those without. Patients whose pancreatic cancers had loss of ATM but normal TP53 had worse overall survival after pancreatic resection. Clin Cancer Res; 20(7); 1865–72. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
ATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577 · cited 1×
“In most cases, ATM mutations are nonsense mutations, giving rise to truncated ATM protein, although other types of mutations have been reported, including missense mutations or in-frame deletions producing catalytically inactive ATM proteins (9).”
BackgroundPancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 2×
“cancers (15), similar to our finding of loss of ATM expression in 11% of sporadic pancreatic cancers in the Hopkins series and in the Emory series.”
BackgroundSelf-citationIacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081 · cited 2×
“At the time we initiated the study we did not have much data to refer to regarding the prevalence of ATM loss in pancreatic cancer or its prognostic significance, so we estimated our study power assuming ATM had a prevalence of 11% and a similar prognostic magnitude of other genes inactivated in pancreatic cancer such…”
BackgroundSelf-citationAtaxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer
Lavin, M. F. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2514 · Cited by 901
The MRE11 complex: at the crossroads of DNA repair and checkpoint signalling
D'Amours, D., & Jackson, S. P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm805 · Cited by 874 · cited 1×
“ATM activation involves interaction with the MRE11-RAD50NBS1 complex to trigger downstream cell-cycle check point activation through phosphorylation of Chk2 and other important substrates, including p53 (27).”
BackgroundExomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
Self-citationCanto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784 · cited 1×
“detection of pancreatic cancer have relied on identifying individuals with an inherited susceptibility to pancreatic cancer and to evaluate the utility of screening these individuals to identify pancreatic cancer precursors and early invasive pancreatic cancers that could be cured with appropriate therapeutic interven…”
BackgroundSelf-citationFrequent detection of pancreatic lesions in asymptomatic high-risk individuals
Canto, M. I., Hruban, R. H., Fishman, E. K., Kamel, I. R., Schulick, R., Zhang, Z., Topazian, M., Takahashi, N., Fletcher, J., Petersen, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.005 · Cited by 648 · cited 1×
“detection of pancreatic cancer have relied on identifying individuals with an inherited susceptibility to pancreatic cancer and to evaluate the utility of screening these individuals to identify pancreatic cancer precursors and early invasive pancreatic cancers that could be cured with appropriate therapeutic interven…”
Self-citationATM Mutations in Patients with Hereditary Pancreatic Cancer
Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0194 · Cited by 491 · cited 6×
“from a patient known to have a germline mutation in ATM and loss of the wild-type ATM allele in their cancer (14).”
BackgroundInfluentialSelf-citation
Cited by
DNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis
Cai, J., Chen, H., Lu, M., Zhang, Y., Lu, B., You, L., Zhang, T., Dai, M., & Zhao, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.027 · Cited by 470
Bang, Y.-J., Im, S.-A., Lee, K.-W., Cho, J. Y., Song, E.-K., Lee, K. H., Kim, Y. H., Park, J. O., Chun, H. G., Zang, D. Y., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0320 · Cited by 290
Boone, B. A., Bahary, N., Zureikat, A. H., Moser, A. J., Normolle, D. P., Wu, W.-C., Singhi, A. D., Bao, P., Bartlett, D. L., Liotta, L. A., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4566-4 · Cited by 234
“However, because only 19 % of the patients assessed had no apparent p53 alterations, this study was underpowered to definitively rule out the contribution of p53 mutational status.(41) It should be noted that although immunohistochemical alterations in p53 expression have 0 p53 WT Median = 21.”
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Metadata
- Authors
- Kim, H., Saka, B., Knight, S., Borges, M., Childs, E., Klein, A., Wolfgang, C., Herman, J., Adsay, V. N., Hruban, R. H., & Goggins, M.
- Venue
- Clinical Cancer Research
- Published
- 2014-03-31
- Volume
- 20
- Issue
- 7
- Pages
- 1865-1872
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2097027018
- Cited by
- 85
- References
- 12
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-1239
- The paper
- Kim, H., Saka, B., Knight, S., Borges, M., Childs, E., Klein, A., Wolfgang, C., Herman, J., Adsay, V. N., Hruban, R. H., & Goggins, M. (2014). Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-1239
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.